Your prediction
Pros and Cons of Merrimack Pharmaceuticals Inc. in the next few years
Pros
?
G***** c******* t* c**********
?
B****
?
M***** P*******
Cons
?
W********* I********* f** t** n*** y****
?
S********** s********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Merrimack Pharmaceuticals Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Merrimack Pharmaceuticals Inc. | - | - | - | - | - | - | - |
| Madrigal Pharmaceuticals inc. | 0.670% | 1.296% | -8.766% | 21.822% | -20.040% | 64.711% | 294.458% |
| Heron Therapeutics Inc. | -0.190% | -3.275% | -22.816% | -41.101% | -11.176% | -59.899% | -93.462% |
| Biocryst Pharmaceuticals | 0.620% | 7.997% | -5.729% | -32.269% | -12.660% | -40.725% | -27.537% |
Comments
Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Show more
Ratings data for MACK provided by MarketBeat
Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Show more
Ratings data for MACK provided by MarketBeat
